Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus Ipilimumab in Metastatic Uveal Melanoma
NCT01585194Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2012
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in Uveal melanoma (UM), sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2012; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT01585194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01585194.